Celldex Therapeutics, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Celldex Therapeutics, Inc. (CLDX) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$13.08 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-26.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-03-26
- Celldex Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was $7.22M.
- Celldex Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was -$8.51M.
- Celldex Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$11.07M.
- Celldex Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $4.07M, a 82.80% decline year-over-year.
- Celldex Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2019 was -$13.08M.
- Celldex Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$15.98M.
- Celldex Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$2.17M.
- Celldex Therapeutics, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$29.65M, a 167.25% decline from fiscal 2015.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-12-31 | -$13.08M 10-K · filed 2020-03-26 | |||
| 2019-03-31 | $7.22M 10-Q · filed 2019-05-07 | -$1.29M derived: sum of 2 quarters · filed 2020-03-26 | -$12.36M derived: sum of 3 quarters · filed 2020-03-26 | -$8.29M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-12-31 | -$8.51M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$19.58M derived: sum of 2 quarters · filed 2020-03-26 | -$15.51M derived: sum of 3 quarters · filed 2020-03-26 | -$15.98M 10-K · filed 2020-03-26 |
| 2018-09-30 | -$11.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$7.00M derived: sum of 2 quarters · filed 2018-11-07 | -$7.46M 10-Q · filed 2018-11-07 | -$21.91M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-06-30 | $4.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $3.61M 10-Q · filed 2018-08-08 | -$10.84M derived: sum of 3 quarters · filed 2020-03-26 | -$22.27M derived: sum of 4 quarters · filed 2020-03-26 |
| 2018-03-31 | -$464.00K 10-Q · filed 2019-05-07 | -$14.91M derived: sum of 2 quarters · filed 2020-03-26 | -$26.34M derived: sum of 3 quarters · filed 2020-03-26 | -$2.67M derived: sum of 4 quarters · filed 2020-03-26 |
| 2017-12-31 | -$14.45M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$25.87M derived: sum of 2 quarters · filed 2020-03-26 | -$2.21M derived: sum of 3 quarters · filed 2020-03-26 | -$2.17M 10-K · filed 2020-03-26 |
| 2017-09-30 | -$11.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $12.24M derived: sum of 2 quarters · filed 2018-11-07 | $12.27M 10-Q · filed 2018-11-07 | $22.99M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $23.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $23.70M 10-Q · filed 2018-08-08 | $34.42M derived: sum of 3 quarters · filed 2019-03-07 | $33.68M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $36.00K 10-Q · filed 2018-05-10 | $10.75M derived: sum of 2 quarters · filed 2019-03-07 | $10.02M derived: sum of 3 quarters · filed 2019-03-07 | -$20.53M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $10.72M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $9.98M derived: sum of 2 quarters · filed 2019-03-07 | -$20.56M derived: sum of 3 quarters · filed 2019-03-07 | -$29.65M 10-K · filed 2019-03-07 |
| 2016-09-30 | -$739.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$31.28M derived: sum of 2 quarters · filed 2017-11-07 | -$40.37M 10-Q · filed 2017-11-07 | -$35.05M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | -$30.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$39.63M 10-Q · filed 2017-08-08 | -$34.31M derived: sum of 3 quarters · filed 2018-03-07 | -$49.10M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | -$9.08M 10-Q · filed 2017-05-09 | -$3.77M derived: sum of 2 quarters · filed 2018-03-07 | -$18.56M derived: sum of 3 quarters · filed 2018-03-07 | -$59.15M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | $5.32M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | -$9.48M derived: sum of 2 quarters · filed 2018-03-07 | -$50.06M derived: sum of 3 quarters · filed 2018-03-07 | $44.09M 10-K · filed 2018-03-07 |
| 2015-09-30 | -$14.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$55.38M derived: sum of 2 quarters · filed 2016-11-07 | $38.77M 10-Q · filed 2016-11-07 | $34.27M derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-06-30 | -$40.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $53.56M 10-Q · filed 2016-08-08 | $49.06M derived: sum of 3 quarters · filed 2017-03-14 | $40.79M derived: sum of 4 quarters · filed 2017-03-14 |
| 2015-03-31 | $94.15M 10-Q · filed 2016-05-05 | $89.64M derived: sum of 2 quarters · filed 2017-03-14 | $81.37M derived: sum of 3 quarters · filed 2017-03-14 | |
| 2014-12-31 | -$4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | -$12.78M derived: sum of 2 quarters · filed 2017-03-14 | -$141.38M 10-K · filed 2017-03-14 | |
| 2014-09-30 | -$8.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$136.88M 10-Q · filed 2015-11-05 | ||
| 2014-06-30 | -$128.60M 10-Q · filed 2015-08-10 | |||
| 2013-12-31 | $144.50M 10-K/A · filed 2016-02-25 | |||
| 2011-06-30 | -$10.46M 10-Q · filed 2011-08-04 | |||
| 2010-06-30 | -$41.84M 10-Q · filed 2011-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |